Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

The safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday that its Imfinzi (durvalumab) has been approved in the European Union as first and only immunotherapy for limited-stage ...

The Cambridge-based pharmaceuticals maker has agreed to pay up to USD1 billion for EsoBiotec SA on a cash and debt free basis. This includes an initial payment of USD425 million on deal closing, and ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

Wealthfront Advisers LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange ...

Astra will buy EsoBiotec for up to £770m comprised of an initial £327m payment and another £443m in the future if it hits agreed milestones.